Stock News & Analysis

They have historically beaten the market, and they aren't done yet.

Explore how portfolio composition and sector weightings set these ETFs apart, offering distinct approaches for international diversification.

E.l.f. Beauty and Vita Coco are building the kind of durable growth stories investors can hold for decades.

Or should you wait for a better entry point?

Compare risk profiles, dividend strategies, and portfolio concentration as these two healthcare ETFs take different paths to long-term returns.

After a monster 623% trailing 10-year total return, investors are wondering what this popular exchange-traded fund can do in the future.

This telehealth stock has fallen hard, but its GLP-1 shift and global expansion could reshape the long-term story. Is the market too skeptical or still too optimistic?

The space economy stock is going through major ups and downs along with the rest of the industry.

You may have options you didn't know existed.

Credo, Cellebrite, and TransMedics are building dominant positions in huge markets with years of expansion still ahead.

Expense ratios and dividend yields set these tech ETFs apart, while portfolio composition reveals key differences in sector exposure and income potential.

The moves you make in the next decade could set you up for success.

Rivian's make-or-break moment is coming next week.

Data, pricing, and scale keep Progressive ahead of rivals.

Elon Musk's next big IPO could be the largest one in history.

These stocks pay between 2.3% and 3.5% in dividends.

SoFi Coach could replace the need for a lot of what financial advisors do.

SpaceX's public market debut could be historic, but Starlink profits, AI spending, and valuation risk pose one of the hardest investor questions in years.

TTAN posts strong results, Lululemon lowers full-year guidance, Bitcoin hits four-month low, and more...

Investors remain hopeful that the Galleri test can gain FDA approval and medical insurance coverage.